Literature DB >> 8469305

Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.

P Hantraye1, M Varastet, M Peschanski, D Riche, P Cesaro, J C Willer, M Maziere.   

Abstract

The progressive degeneration of dopamine neurons observed in idiopathic Parkinson's disease was mimicked by injecting low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to baboons, on a chronic basis. Five Papio papio baboons were treated on two different regimens (chronic intravenous administration at weekly intervals for 20-21 months or, daily MPTP treatment for five days followed five to six months later by chronic weekly injections for 5-21.5 months). All animals were assessed for motor symptoms during and after neurotoxic treatment. Both regimens invariably resulted in the appearance of a progressive and irreversible syndrome characterized by action and resting tremor, cogwheel rigidity, postural impairments, hypokinesia and bradykinesia. In some animals, symptoms of resting tremor and rigidity initially restricted to one side of the body became bilateral within a few months of treatment. Subtle abnormalities that may be found in idiopathic Parkinson's disease such as alterations of the blink reflex response were also noted. Neuropathological examination of caudate nucleus, putamen, substantia nigra and ventral tegmental area in brain sections stained for tyrosine hydroxylase showed a typical uneven striatal dopamine fibre loss and a neuronal depletion in the dopaminergic mesencephalic cell groups that reproduce those observed in idiopathic Parkinson's disease. Immunocytochemical observations and behavioural data show that chronic rather than acute MPTP injection regimens can replicate most of the neuropathological and the clinical features typical of idiopathic Parkinson's disease, possibly by increasing the ability of this neurotoxin to target specific subpopulations of mesencephalic dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8469305     DOI: 10.1016/0306-4522(93)90295-q

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  17 in total

1.  Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production.

Authors:  Zhi-Guo Zhang; Lin Wu; Ju-Lei Wang; Jian-Dong Yang; Jing Zhang; Jian Zhang; Li-Hong Li; Yi Xia; Li-Bo Yao; Huai-Zhou Qin; Guo-Dong Gao
Journal:  Mol Cell Biochem       Date:  2012-01-26       Impact factor: 3.396

2.  Time dependent alterations of co-localization of S100beta and GFAP in the MPTP-treated mice.

Authors:  T Himeda; Y Watanabe; H Tounai; N Hayakawa; H Kato; T Araki
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

3.  Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Olivia Groover; Yoland Smith
Journal:  Neurobiol Dis       Date:  2016-12-30       Impact factor: 5.996

Review 4.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes.

Authors:  Lei Xia; Dianxuan Guo; Bing Chen
Journal:  Exp Ther Med       Date:  2017-09-29       Impact factor: 2.447

6.  Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.

Authors:  B J Snow; F J Vingerhoets; J W Langston; J W Tetrud; V Sossi; D B Calne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 7.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

8.  Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.

Authors:  Feng Ding; Liming Luan; Yi Ai; Ashley Walton; Greg A Gerhardt; Don M Gash; Richard Grondin; Zhiming Zhang
Journal:  Exp Neurol       Date:  2008-05-03       Impact factor: 5.330

9.  Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease.

Authors:  R M Villalba; T Wichmann; Y Smith
Journal:  Brain Struct Funct       Date:  2013-03-19       Impact factor: 3.270

Review 10.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.